AstraZeneca is looking for partnerships in infectious disease therapeutics
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
The Infection group aims to discover and develop effective, targeted therapies to address unmet needs in serious bacterial, fungal or viral infections and neglected diseases, using both small-molecule and biologic/vaccine approaches.
AstraZeneca, with their strategic partners, has one of the world’s largest antibacterial pipelines targeting serious bacterial infections. Their partnership interests include: viral infections such as respiratory viruses (e.g flu, RSV), HCV, HBV and herpes family viruses, as well as systemic fungal infections, and diagnostics. Novel vaccines to address bacterial and viral infections with limited current treatment options are also of interest.
They aim to deliver solutions for diseases of the developing world (viral, parasitic and bacterial) through innovative partnerships with academics, NGOs and peer companies.